Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer.
Sakamoto S, Sato K, Kimura T, Matsui Y, Shiraishi Y, Hashimoto K, Miyake H, Narita S, Miki J, Matsumoto R, Kato T, Saito T, Tomida R, Shiota M, Joraku A, Terada N, Suekane S, Kaneko T, Tatarano S, Yoshio Y, Yoshino T, Nishiyama N, Kawakami E, Ichikawa T, Kitamura H. Sakamoto S, et al. Among authors: suekane s. Sci Rep. 2024 Jul 3;14(1):15307. doi: 10.1038/s41598-024-65969-3. Sci Rep. 2024. PMID: 38961131 Free PMC article.
Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K. Noguchi M, et al. Among authors: suekane s. Oncol Res. 2007;16(7):341-9. doi: 10.3727/000000006783980955. Oncol Res. 2007. PMID: 17518272 Clinical Trial.
88 results